Patients' Age Is Important When Setting Priorities

Published Jul 23, 2013
Tromsø, Norway - Several studies on priority setting preferences have shown that people think that differences both in patients’ ageand in remaining lifetime should be taken into account. Researchers from the University of Tromsø in Norway set out to determine what is more important: A patient’s age or their remaining lifetime if left untreated? Survey results from a Norwegian population sample provided strong support for the ‘fair innings’ argument that total lifetime inequalities should be reduced.  Differences in patients’ remaining lifetime without treatment did not matter, implying little support for the ‘end of life’ argument that a short life expectancy makes patients entitled to preferential treatment. When faced with pairwise choices between hypothetical patients, the majority of respondents would prioritise the younger patient even if the older patient had shorter remaining lifetime if left untreated. Professor Jan Abel Olsen, PhD, lead author on the study states, "It is more important to reduce inequalities in people's total lifetime than in their remaining lifetime."  The full study, “Priority Preferences: “End of Life” Does Not Matter, But Total Life Does,” is published inValue in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×